H.B. 30 Enrolled

1

DRUG LAW AMENDMENTS
2 2010 GENERAL SESSION
3 STATE OF UTAH
4 Chief Sponsor: Trisha S. Beck
5 Senate Sponsor: Curtis S. Bramble
6 Cosponsors:
7 Bradley M. DawPaul Ray
Phil RiesenStephen E. Sandstrom
Evan J. Vickers 8
9 LONG TITLE
10 General Description:
11 This bill modifies Title 58, Chapter 37, Utah Controlled Substances Act, regarding
12 Schedule IV substances.
13 Highlighted Provisions:
14 This bill:
15 . adds carisoprodol, which has the brand name of Soma, as a Schedule IV drug.
16 Monies Appropriated in this Bill:
17 None
18 Other Special Clauses:
19 None
20 Utah Code Sections Affected:
21 AMENDS:
22 58-37-4, as last amended by Laws of Utah 2006, Chapter 8
23
24 Be it enacted by the Legislature of the state of Utah:
25 Section 1. Section 58-37-4 is amended to read:
26 58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings
27 required -- Specific substances included in schedules.
28 (1) There are established five schedules of controlled substances known as Schedules
29 I, II, III, IV, and V which shall consist of substances listed in this section.

30 (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by
31 the official name, common or usual name, chemical name, or brand name designated:
32 (a) Schedule I:
33 (i) Unless specifically excepted or unless listed in another schedule, any of the
34 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
35 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the
36 specific chemical designation:
37 (A) Acetyl-alpha-methylfentanyl
38 (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
39 (B) Acetylmethadol;
40 (C) Allylprodine;
41 (D) Alphacetylmethadol, except levo-alphacetylmethadol also known as
42 levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
43 (E) Alphameprodine;
44 (F) Alphamethadol;
45 (G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
46 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
47 (H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
48 piperidinyl]-N-phenylpropanamide);
49 (I) Benzethidine;
50 (J) Betacetylmethadol;
51 (K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
52 piperidinyl]-N-phenylpropanamide);
53 (L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
54 phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
55 (M) Betameprodine;
56 (N) Betamethadol;
57 (O) Betaprodine;

58 (P) Clonitazene;
59 (Q) Dextromoramide;
60 (R) Diampromide;
61 (S) Diethylthiambutene;
62 (T) Difenoxin;
63 (U) Dimenoxadol;
64 (V) Dimepheptanol;
65 (W) Dimethylthiambutene;
66 (X) Dioxaphetyl butyrate;
67 (Y) Dipipanone;
68 (Z) Ethylmethylthiambutene;
69 (AA) Etonitazene;
70 (BB) Etoxeridine;
71 (CC) Furethidine;
72 (DD) Hydroxypethidine;
73 (EE) Ketobemidone;
74 (FF) Levomoramide;
75 (GG) Levophenacylmorphan;
76 (HH) Morpheridine;
77 (II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
78 (JJ) Noracymethadol;
79 (KK) Norlevorphanol;
80 (LL) Normethadone;
81 (MM) Norpipanone;
82 (NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
83 propanamide;
84 (OO) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
85 (PP) Phenadoxone;

86 (QQ) Phenampromide;
87 (RR) Phenomorphan;
88 (SS) Phenoperidine;
89 (TT) Piritramide;
90 (UU) Proheptazine;
91 (VV) Properidine;
92 (WW) Propiram;
93 (XX) Racemoramide;
94 (YY) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
95 (ZZ) Tilidine;
96 (AAA) Trimeperidine;
97 (BBB) 3-methylfentanyl, including the optical and geometric isomers
98 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
99 (CCC) 3-methylthiofentanyl
100 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
101 (ii) Unless specifically excepted or unless listed in another schedule, any of the
102 following opium derivatives, their salts, isomers, and salts of isomers when the existence of
103 the salts, isomers, and salts of isomers is possible within the specific chemical designation:
104 (A) Acetorphine;
105 (B) Acetyldihydrocodeine;
106 (C) Benzylmorphine;
107 (D) Codeine methylbromide;
108 (E) Codeine-N-Oxide;
109 (F) Cyprenorphine;
110 (G) Desomorphine;
111 (H) Dihydromorphine;
112 (I) Drotebanol;
113 (J) Etorphine (except hydrochloride salt);

114 (K) Heroin;
115 (L) Hydromorphinol;
116 (M) Methyldesorphine;
117 (N) Methylhydromorphine;
118 (O) Morphine methylbromide;
119 (P) Morphine methylsulfonate;
120 (Q) Morphine-N-Oxide;
121 (R) Myrophine;
122 (S) Nicocodeine;
123 (T) Nicomorphine;
124 (U) Normorphine;
125 (V) Pholcodine; and
126 (W) Thebacon.
127 (iii) Unless specifically excepted or unless listed in another schedule, any material,
128 compound, mixture, or preparation which contains any quantity of the following
129 hallucinogenic substances, or which contains any of their salts, isomers, and salts of isomers
130 when the existence of the salts, isomers, and salts of isomers is possible within the specific
131 chemical designation; as used in this Subsection (2)(iii) only, "isomer" includes the optical,
132 position, and geometric isomers:
133 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
134 .-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; .-ET; and AET;
135 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
136 4-bromo-2,5-dimethoxy-.-methylphenethylamine; 4-bromo-2,5-DMA;
137 (C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
138 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
139 (D) 2,5-dimethoxyamphetamine, some trade or other names:
140 2,5-dimethoxy-.-methylphenethylamine; 2,5-DMA;
141 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;

142 (F) 4-methoxyamphetamine, some trade or other names:
143 4-methoxy-.-methylphenethylamine; paramethoxyamphetamine, PMA;
144 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
145 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
146 4-methyl-2,5-dimethoxy-.-methylphenethylamine; "DOM"; and "STP";
147 (I) 3,4-methylenedioxy amphetamine;
148 (J) 3,4-methylenedioxymethamphetamine (MDMA);
149 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
150 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
151 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
152 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
153 (M) 3,4,5-trimethoxy amphetamine;
154 (N) Bufotenine, some trade and other names:
155 3-(.-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,
156 N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
157 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
158 (P) Dimethyltryptamine, some trade or other names: DMT;
159 (Q) Ibogaine, some trade and other names:
160 7-Ethyl-6,6.,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
161 [5,4-b] indole; Tabernanthe iboga;
162 (R) Lysergic acid diethylamide;
163 (S) Marijuana;
164 (T) Mescaline;
165 (U) Parahexyl, some trade or other names:
166 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
167 (V) Peyote, meaning all parts of the plant presently classified botanically as
168 Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from
169 any part of such plant, and every compound, manufacture, salts, derivative, mixture, or

170 preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
171 (W) N-ethyl-3-piperidyl benzilate;
172 (X) N-methyl-3-piperidyl benzilate;
173 (Y) Psilocybin;
174 (Z) Psilocyn;
175 (AA) Tetrahydrocannabinols, synthetic equivalents of the substances contained in the
176 plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,
177 and their isomers with similar chemical structure and pharmacological activity such as the
178 following: .1 cis or trans tetrahydrocannabinol, and their optical isomers .6 cis or trans
179 tetrahydrocannabinol, and their optical isomers .3,4 cis or trans tetrahydrocannabinol, and its
180 optical isomers, and since nomenclature of these substances is not internationally
181 standardized, compounds of these structures, regardless of numerical designation of atomic
182 positions covered;
183 (BB) Ethylamine analog of phencyclidine, some trade or other names:
184 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
185 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
186 (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
187 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
188 (DD) Thiophene analog of phencyclidine, some trade or other names:
189 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
190 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
191 (iv) Unless specifically excepted or unless listed in another schedule, any material
192 compound, mixture, or preparation which contains any quantity of the following substances
193 having a depressant effect on the central nervous system, including its salts, isomers, and salts
194 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
195 specific chemical designation:
196 (A) Mecloqualone; and
197 (B) Methaqualone.

198 (v) Any material, compound, mixture, or preparation containing any quantity of the
199 following substances having a stimulant effect on the central nervous system, including their
200 salts, isomers, and salts of isomers:
201 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
202 4,5-dihydro-5-phenyl-2-oxazolamine;
203 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
204 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
205 (C) Fenethylline;
206 (D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
207 alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
208 alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
209 methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts
210 of optical isomers;
211 (E) (.)cis-4-methylaminorex ((.)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
212 (F) N-ethylamphetamine; and
213 (G) N,N-dimethylamphetamine, also known as
214 N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
215 (vi) Any material, compound, mixture, or preparation which contains any quantity of
216 the following substances, including their optical isomers, salts, and salts of isomers, subject to
217 temporary emergency scheduling:
218 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
219 (B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
220 (vii) Unless specifically excepted or unless listed in another schedule, any material,
221 compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
222 (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
223 (b) Schedule II:
224 (i) Unless specifically excepted or unless listed in another schedule, any of the
225 following substances whether produced directly or indirectly by extraction from substances of

226 vegetable origin, or independently by means of chemical synthesis, or by a combination of
227 extraction and chemical synthesis:
228 (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
229 opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and
230 naltrexone, and their respective salts, but including:
231 (I) Raw opium;
232 (II) Opium extracts;
233 (III) Opium fluid;
234 (IV) Powdered opium;
235 (V) Granulated opium;
236 (VI) Tincture of opium;
237 (VII) Codeine;
238 (VIII) Ethylmorphine;
239 (IX) Etorphine hydrochloride;
240 (X) Hydrocodone;
241 (XI) Hydromorphone;
242 (XII) Metopon;
243 (XIII) Morphine;
244 (XIV) Oxycodone;
245 (XV) Oxymorphone; and
246 (XVI) Thebaine;
247 (B) Any salt, compound, derivative, or preparation which is chemically equivalent or
248 identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
249 substances may not include the isoquinoline alkaloids of opium;
250 (C) Opium poppy and poppy straw;
251 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
252 any salt, compound, derivative, or preparation which is chemically equivalent or identical with
253 any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,

254 and salts of isomers and derivatives, whether derived from the coca plant or synthetically
255 produced, except the substances may not include decocainized coca leaves or extraction of
256 coca leaves, which extractions do not contain cocaine or ecgonine; and
257 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in
258 either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium
259 poppy.
260 (ii) Unless specifically excepted or unless listed in another schedule, any of the
261 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
262 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the
263 specific chemical designation, except dextrorphan and levopropoxyphene:
264 (A) Alfentanil;
265 (B) Alphaprodine;
266 (C) Anileridine;
267 (D) Bezitramide;
268 (E) Bulk dextropropoxyphene (nondosage forms);
269 (F) Carfentanil;
270 (G) Dihydrocodeine;
271 (H) Diphenoxylate;
272 (I) Fentanyl;
273 (J) Isomethadone;
274 (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
275 levomethadyl acetate, or LAAM;
276 (L) Levomethorphan;
277 (M) Levorphanol;
278 (N) Metazocine;
279 (O) Methadone;
280 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
281 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic

282 acid;
283 (R) Pethidine (meperidine);
284 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
285 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
286 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
287 (V) Phenazocine;
288 (W) Piminodine;
289 (X) Racemethorphan;
290 (Y) Racemorphan;
291 (Z) Remifentanil; and
292 (AA) Sufentanil.
293 (iii) Unless specifically excepted or unless listed in another schedule, any material,
294 compound, mixture, or preparation which contains any quantity of the following substances
295 having a stimulant effect on the central nervous system:
296 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
297 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
298 (C) Phenmetrazine and its salts; and
299 (D) Methylphenidate.
300 (iv) Unless specifically excepted or unless listed in another schedule, any material,
301 compound, mixture, or preparation which contains any quantity of the following substances
302 having a depressant effect on the central nervous system, including its salts, isomers, and salts
303 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
304 specific chemical designation:
305 (A) Amobarbital;
306 (B) Glutethimide;
307 (C) Pentobarbital;
308 (D) Phencyclidine;
309 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and

310 1-piperidinocyclohexanecarbonitrile (PCC); and
311 (F) Secobarbital.
312 (v) (A) Unless specifically excepted or unless listed in another schedule, any material,
313 compound, mixture, or preparation which contains any quantity of Phenylacetone.
314 (B) Some of these substances may be known by trade or other names:
315 phenyl-2-propanone[,]; P2P; benzyl methyl ketone[,]; and methyl benzyl ketone.
316 (vi) Nabilone, another name for nabilone:
317 (.)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
318 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
319 (c) Schedule III:
320 (i) Unless specifically excepted or unless listed in another schedule, any material,
321 compound, mixture, or preparation which contains any quantity of the following substances
322 having a stimulant effect on the central nervous system, including its salts, isomers whether
323 optical, position, or geometric, and salts of the isomers when the existence of the salts,
324 isomers, and salts of isomers is possible within the specific chemical designation:
325 (A) Those compounds, mixtures, or preparations in dosage unit form containing any
326 stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
327 listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
328 Code of Federal Regulations, and any other drug of the quantitive composition shown in that
329 list for those drugs or which is the same except that it contains a lesser quantity of controlled
330 substances;
331 (B) Benzphetamine;
332 (C) Chlorphentermine;
333 (D) Clortermine; and
334 (E) Phendimetrazine.
335 (ii) Unless specifically excepted or unless listed in another schedule, any material,
336 compound, mixture, or preparation which contains any quantity of the following substances
337 having a depressant effect on the central nervous system:

338 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
339 pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
340 which are not listed in any schedule;
341 (B) Any suppository dosage form containing amobarbital, secobarbital, or
342 pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
343 Administration for marketing only as a suppository;
344 (C) Any substance which contains any quantity of a derivative of barbituric acid or
345 any salt of any of them;
346 (D) Chlorhexadol;
347 (E) Buprenorphine;
348 (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
349 isomers, and salts of isomers, for which an application is approved under the federal Food,
350 Drug, and Cosmetic Act, Section 505;
351 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
352 . -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
353 (H) Lysergic acid;
354 (I) Lysergic acid amide;
355 (J) Methyprylon;
356 (K) Sulfondiethylmethane;
357 (L) Sulfonethylmethane;
358 (M) Sulfonmethane; and
359 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
360 tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
361 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
362 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
363 flupyrazapon.
364 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in
365 a U.S. Food and Drug Administration approved drug product, some other names for

366 dronabinol:
367 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
368 (-)-delta-9-(trans)-tetrahydrocannabinol.
369 (iv) Nalorphine.
370 (v) Unless specifically excepted or unless listed in another schedule, any material,
371 compound, mixture, or preparation containing limited quantities of any of the following
372 narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
373 (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
374 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of
375 opium;
376 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
377 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
378 therapeutic amounts;
379 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
380 than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline
381 alkaloid of opium;
382 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
383 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
384 recognized therapeutic amounts;
385 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
386 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
387 therapeutic amounts;
388 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
389 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
390 recognized therapeutic amounts;
391 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or
392 not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients
393 in recognized therapeutic amounts; and

394 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
395 with one or more active, non-narcotic ingredients in recognized therapeutic amounts.
396 (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids
397 including any of the following or any isomer, ester, salt, or derivative of the following that
398 promotes muscle growth:
399 (A) Boldenone;
400 (B) Chlorotestosterone (4-chlortestosterone);
401 (C) Clostebol;
402 (D) Dehydrochlormethyltestosterone;
403 (E) Dihydrotestosterone (4-dihydrotestosterone);
404 (F) Drostanolone;
405 (G) Ethylestrenol;
406 (H) Fluoxymesterone;
407 (I) Formebulone (formebolone);
408 (J) Mesterolone;
409 (K) Methandienone;
410 (L) Methandranone;
411 (M) Methandriol;
412 (N) Methandrostenolone;
413 (O) Methenolone;
414 (P) Methyltestosterone;
415 (Q) Mibolerone;
416 (R) Nandrolone;
417 (S) Norethandrolone;
418 (T) Oxandrolone;
419 (U) Oxymesterone;
420 (V) Oxymetholone;
421 (W) Stanolone;

422 (X) Stanozolol;
423 (Y) Testolactone;
424 (Z) Testosterone; and
425 (AA) Trenbolone.
426 (vii) Anabolic steroids expressly intended for administration through implants to cattle
427 or other nonhuman species, and approved by the Secretary of Health and Human Services for
428 use, may not be classified as a controlled substance.
429 (d) Schedule IV:
430 (i) Unless specifically excepted or unless listed in another schedule, any material,
431 compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
432 less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.
433 (ii) Unless specifically excepted or unless listed in another schedule, any material,
434 compound, mixture, or preparation which contains any quantity of the following substances,
435 including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
436 salts of isomers is possible within the specific chemical designation:
437 (A) Alprazolam;
438 (B) Barbital;
439 (C) Bromazepam;
440 (D) Butorphanol;
441 (E) Camazepam;
442 (F) Carisoprodol;
443 [(F)] (G) Chloral betaine;
444 [(G)] (H) Chloral hydrate;
445 [(H)] (I) Chlordiazepoxide;
446 [(I)] (J) Clobazam;
447 [(J)] (K) Clonazepam;
448 [(K)] (L) Clorazepate;
449 [(L)] (M) Clotiazepam;

450 [(M)] (N) Cloxazolam;
451 [(N)] (O) Delorazepam;
452 [(O)] (P) Diazepam;
453 [(P)] (Q) Dichloralphenazone;
454 [(Q)] (R) Estazolam;
455 [(R)] (S) Ethchlorvynol;
456 [(S)] (T) Ethinamate;
457 [(T)] (U) Ethyl loflazepate;
458 [(U)] (V) Fludiazepam;
459 [(V)] (W) Flunitrazepam;
460 [(W)] (X) Flurazepam;
461 [(X)] (Y) Halazepam;
462 [(Y)] (Z) Haloxazolam;
463 [(Z)] (AA) Ketazolam;
464 [(AA)] (BB) Loprazolam;
465 [(BB)] (CC) Lorazepam;
466 [(CC)] (DD) Lormetazepam;
467 [(DD)] (EE) Mebutamate;
468 [(EE)] (FF) Medazepam;
469 [(FF)] (GG) Meprobamate;
470 [(GG)] (HH) Methohexital;
471 [(HH)] (II) Methylphenobarbital (mephobarbital);
472 [(II)] (JJ) Midazolam;
473 [(JJ)] (KK) Nimetazepam;
474 [(KK)] (LL) Nitrazepam;
475 [(LL)] (MM) Nordiazepam;
476 [(MM)] (NN) Oxazepam;
477 [(NN)] (OO) Oxazolam;

478 [(OO)] (PP) Paraldehyde;
479 [(PP)] (QQ) Pentazocine;
480 [(QQ)] (RR) Petrichloral;
481 [(RR)] (SS) Phenobarbital;
482 [(SS)] (TT) Pinazepam;
483 [(TT)] (UU) Prazepam;
484 [(UU)] (VV) Quazepam;
485 [(VV)] (WW) Temazepam;
486 [(WW)] (XX) Tetrazepam;
487 [(XX)] (YY) Triazolam;
488 [(YY)] (ZZ) Zaleplon; and
489 [(ZZ)] (AAA) Zolpidem.
490 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
491 any quantity of the following substances, including its salts, isomers whether optical, position,
492 or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
493 isomers is possible.
494 (iv) Unless specifically excepted or unless listed in another schedule, any material,
495 compound, mixture, or preparation which contains any quantity of the following substances
496 having a stimulant effect on the central nervous system, including its salts, isomers whether
497 optical, position, or geometric isomers, and salts of the isomers when the existence of the salts,
498 isomers, and salts of isomers is possible within the specific chemical designation:
499 (A) Cathine ((+)-norpseudoephedrine);
500 (B) Diethylpropion;
501 (C) Fencamfamine;
502 (D) Fenproprex;
503 (E) Mazindol;
504 (F) Mefenorex;
505 (G) Modafinil;

506 (H) Pemoline, including organometallic complexes and chelates thereof;
507 (I) Phentermine;
508 (J) Pipradrol;
509 (K) Sibutramine; and
510 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
511 (v) Unless specifically excepted or unless listed in another schedule, any material,
512 compound, mixture, or preparation which contains any quantity of dextropropoxyphene
513 (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
514 (e) Schedule V: Any compound, mixture, or preparation containing any of the
515 following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous
516 base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in
517 sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal
518 qualities other than those possessed by the narcotic drug alone:
519 (i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
520 (ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
521 grams;
522 (iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
523 grams;
524 (iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
525 atropine sulfate per dosage unit;
526 (v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
527 (vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
528 atropine sulfate per dosage unit; and
529 (vii) unless specifically exempted or excluded or unless listed in another schedule, any
530 material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant
531 effect on the central nervous system, including its salts, isomers, and salts of isomers.